TY - JOUR
T1 - TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer
T2 - a preliminary study
AU - Fujiwara, Sho
AU - Saiki, Yuriko
AU - Fukushige, Shinichi
AU - Yamanaka, Mie
AU - Ishida, Masaharu
AU - Motoi, Fuyuhiko
AU - Unno, Michiaki
AU - Horii, Akira
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/5
Y1 - 2023/5
N2 - Recent advances in the development of chemotherapies have helped improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). However, predicting factors for the outcomes of chemotherapies (either gemcitabine or S-1) have not yet been established. We analyzed the expression of 4 major epithelial-to-mesenchymal transition-inducing transcription factors in 38 PDAC patients who received adjuvant chemotherapy after radical resection to examine the association with patients’ prognoses. The TWIST1-positive group showed a significantly poorer prognosis than the TWIST1-negative group for both the relapse‐free survival (median survival time [MST] of 8.9 vs. 18.5 months, P = 0.016) and the overall survival (MST of 15.2 vs. 33.4 months, P = 0.023). A multivariate analysis revealed that TWIST1 positivity was an independent prognostic factor for a poor response to adjuvant chemotherapies (hazard ratio 2.61; 95% confidence interval 1.10–6.79; P = 0.029). These results suggest that TWIST1 can be utilized as an important poor prognostic factor for radically resected PDAC patients with adjuvant chemotherapy, potentially including neoadjuvant therapy using these agents.
AB - Recent advances in the development of chemotherapies have helped improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). However, predicting factors for the outcomes of chemotherapies (either gemcitabine or S-1) have not yet been established. We analyzed the expression of 4 major epithelial-to-mesenchymal transition-inducing transcription factors in 38 PDAC patients who received adjuvant chemotherapy after radical resection to examine the association with patients’ prognoses. The TWIST1-positive group showed a significantly poorer prognosis than the TWIST1-negative group for both the relapse‐free survival (median survival time [MST] of 8.9 vs. 18.5 months, P = 0.016) and the overall survival (MST of 15.2 vs. 33.4 months, P = 0.023). A multivariate analysis revealed that TWIST1 positivity was an independent prognostic factor for a poor response to adjuvant chemotherapies (hazard ratio 2.61; 95% confidence interval 1.10–6.79; P = 0.029). These results suggest that TWIST1 can be utilized as an important poor prognostic factor for radically resected PDAC patients with adjuvant chemotherapy, potentially including neoadjuvant therapy using these agents.
KW - Epithelial-to-mesenchymal transition
KW - Neoadjuvant chemotherapy
KW - TWIST1
UR - http://www.scopus.com/inward/record.url?scp=85147744268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147744268&partnerID=8YFLogxK
U2 - 10.1007/s00595-023-02655-3
DO - 10.1007/s00595-023-02655-3
M3 - Article
C2 - 36764935
AN - SCOPUS:85147744268
SN - 0941-1291
VL - 53
SP - 633
EP - 639
JO - Surgery Today
JF - Surgery Today
IS - 5
ER -
